Location of Metastases: Liver

NCT05351294: Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Management

NCT05351294
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain, Bone, Liver
Additional Notes: Patients must be planning, or actively receiving, systemic therapy (e.g. chemotherapy, targeted/biologic therapy, immunotherapy, or hormonal therapy)
Exclusions: Patients who are responsive to hormonal therapy; Patients with history of whole brain radiation therapy for brain metastases (patients who underwent one prior treatment with radiosurgery for brain metastases are eligible)
https://ClinicalTrials.gov/show/NCT05351294

NCT05303038: Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

NCT05303038
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: Liver
Additional Notes: 
Exclusions: Patients with brain metastases; Patients without more than 2 prior lines systemic therapy
https://ClinicalTrials.gov/show/NCT05303038

Up ↑